

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution, mouthwash

Tablet

CAUTIONARY AND ADVISORY LABELS 8, 21, 27

▶ **Allopurinol (Non-proprietary)****Allopurinol 100 mg** Allopurinol 100mg tablets | 28 tablet [PoM]

£8.15 DT = £1.72

Allopurinol 300 mg Allopurinol 300mg tablets | 28 tablet [PoM]

£8.53 DT = £6.35

▶ **Uricto (Ennogen Pharma Ltd)****Allopurinol 100 mg** Uricto 100mg tablets | 28 tablet [PoM] £0.78 DT = £1.72**Allopurinol 300 mg** Uricto 300mg tablets | 28 tablet [PoM] £1.85 DT = £6.35▶ **Zyloric (Aspen Pharma Trading Ltd)****Allopurinol 100 mg** Zyloric 100mg tablets | 100 tablet [PoM] £10.19**Allopurinol 300 mg** Zyloric 300mg tablets | 28 tablet [PoM] £7.31 DT = £6.35

3 Immunotherapy responsive malignancy

IMMUNOSTIMULANTS > INTERFERONS

Interferon alfa

30-Mar-2017

- **DRUG ACTION** Interferon alfa has shown some antitumour effect in certain lymphomas and solid tumours.

- **INDICATIONS AND DOSE**

Induction of early regression of life-threatening corticosteroid resistant haemangioma of infancy

▶ BY SUBCUTANEOUS INJECTION

- ▶ Child: (consult local protocol)

INTRONA[®] PEN**Chronic active hepatitis B**

▶ BY SUBCUTANEOUS INJECTION

- ▶ Child 2–17 years: 5 000 000–10 000 000 units/m² 3 times a week

Chronic active hepatitis C (in combination with oral ribavirin)

▶ BY SUBCUTANEOUS INJECTION

- ▶ Child 3–17 years: 3 000 000 units/m² 3 times a week

INTRONA[®] VIALS**Chronic active hepatitis B**

▶ BY SUBCUTANEOUS INJECTION

- ▶ Child 2–17 years: 5 000 000–10 000 000 units/m² 3 times a week

Chronic active hepatitis C (in combination with ribavirin)

▶ BY SUBCUTANEOUS INJECTION

- ▶ Child 3–17 years: 3 000 000 units/m² 3 times a week

ROFERON-A[®]**Chronic active hepatitis B**

▶ BY SUBCUTANEOUS INJECTION

- ▶ Child 2–17 years: 2 500 000–5 000 000 units/m² 3 times a week, up to 10 000 000 units/m² has been used 3 times a week

- **UNLICENSED USE** Not licensed for use in children for chronic active hepatitis B.

ROFERON-A[®] Roferon-A[®] not licensed for use in children.

- **CONTRA-INDICATIONS** Avoid injections containing benzyl alcohol in neonates · history of severe psychiatric illness

CONTRA-INDICATIONS, FURTHER INFORMATION

For contra-indications consult product literature and local treatment protocol.

- **CAUTIONS**

CAUTIONS, FURTHER INFORMATION For cautions consult product literature and local treatment protocol.

Interferon alfa should always be used under the close supervision of a specialist; the decision to treat should be made only after careful assessment of the expected benefits versus the potential risks, in particular the risk of growth inhibition caused by combination therapy.

- **INTERACTIONS** → Appendix 1: interferons

- **SIDE-EFFECTS**

- ▶ **Common or very common** Alopecia · anaemia · anxiety · appetite abnormal · arthralgia · asthenia · behaviour abnormal · chest pain · chills · concentration impaired · confusion · conjunctivitis · constipation · cough · depression · diarrhoea · dizziness · drowsiness · dysphonia · dyspnoea · epistaxis · eye pain · fever · flushing · gastrointestinal discomfort · gastrointestinal disorders · growth retardation · headache · hepatic function abnormal · hyperhidrosis · hyperkinesia · hyperthyroidism · hypertriglyceridaemia (sometimes severe) · hyperuricaemia · hypothyroidism · increased risk of infection · influenza like illness · lacrimation disorder · lymphadenopathy · malaise · menstrual cycle irregularities · mood altered · musculoskeletal pain · myalgia · nail disorder · nasal complaints · nausea · neoplasms · neutropenia · oedema · oral disorders · pallor · photosensitivity reaction · sensation abnormal · skin reactions · sleep disorders · suicidal ideation · tachypnoea · testicular pain · thrombocytopenia · tremor · urinary disorders · vaginal disorder · virilism · visual impairment · vomiting

SIDE-EFFECTS, FURTHER INFORMATION Respiratory symptoms should be investigated and if pulmonary infiltrates are suspected or lung function is impaired the discontinuation of interferon alfa should be considered.

- **CONCEPTION AND CONTRACEPTION** Effective contraception required during treatment—consult product literature.

- **PREGNANCY** Avoid unless potential benefit outweighs risk (toxicity in animal studies).

- **BREAST FEEDING** Unlikely to be harmful.

- **HEPATIC IMPAIRMENT** Manufacturer advises caution in mild to moderate impairment; avoid in severe impairment. **Monitoring** Close monitoring required in mild to moderate hepatic impairment.

- **RENAL IMPAIRMENT** Avoid in severe renal impairment. **Monitoring** Close monitoring required in mild to moderate renal impairment.

- **MONITORING REQUIREMENTS**

- ▶ Monitoring of lipid concentration is recommended.
- ▶ Monitoring of hepatic function is recommended.

- **DIRECTIONS FOR ADMINISTRATION**

INTRONA[®] VIALS IntronA[®] injection vials for subcutaneous injection or intravenous infusion.**ROFERON-A[®]** Roferon-A[®] injection for subcutaneous injection.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

Solution for injection

EXCIPIENTS: May contain Benzyl alcohol

▶ **IntronA** (Merck Sharp & Dohme Ltd)**Interferon alfa-2b 10 mega u per 1 ml** IntronA 10million units/1ml

solution for injection vials | 1 vial [PoM] [S]

IntronA 25million units/2.5ml solution for injection multidose vials |

1 vial [PoM] £103.94

Interferon alfa-2b 15 mega u per 1 ml IntronA 18million units/1.2ml

solution for injection multidose pens | 1 pre-filled disposable

injection [PoM] £74.83